Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Construction in Progress: 2021-2022

Historic Construction in Progress for SAB Biotherapeutics (SABS) over the last 2 years, with Dec 2022 value amounting to $308,317.

  • SAB Biotherapeutics' Construction in Progress was N/A to $329,617 in Q1 2023 from the same period last year, while for Mar 2023 it was $329,617, marking a year-over-year change of. This contributed to the annual value of $308,317 for FY2022, which is 93.31% down from last year.
  • As of FY2022, SAB Biotherapeutics' Construction in Progress stood at $308,317, which was down 93.31% from $4.6 million recorded in FY2021.
  • In the past 5 years, SAB Biotherapeutics' Construction in Progress registered a high of $4.6 million during FY2021, and its lowest value of $308,317 during FY2022.
  • Moreover, its 2-year median value for Construction in Progress was $2.5 million (2021), whereas its average is $2.5 million.
  • Data for SAB Biotherapeutics' Construction in Progress shows a maximum YoY slumped of 93.31% (in 2022) over the last 5 years.
  • SAB Biotherapeutics' Construction in Progress (Yearly) stood at $4.6 million in 2021, then crashed by 93.31% to $308,317 in 2022.